GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, announced that Senthil Ranganathan, PhD, Vice President, Technical Development and CMC Operations, will present at the World Vaccine Congress Europe 2026, taking place October 19–22 at the RAI Amsterdam in the Netherlands. The presentation, titled “Revolutionizing MVA – Single Dose and Continuous Cell-Line Manufacturing,” will highlight the company’s progress in advancing next-generation Modified Vaccinia Ankara (MVA) technologies. This matters because MVA is a well-established vaccine platform increasingly vital for combating emerging infectious diseases and biodefense threats, yet its broader use has been limited by multi-dose regimens and manufacturing constraints.
Dr. Ranganathan’s talk will focus on two complementary objectives: achieving robust immunity with a single vaccine administration and establishing a scalable continuous cell-line manufacturing platform. GeoVax’s MVA-X technology aims to enhance immune responses and enable effective single-dose vaccination. Preclinical studies have shown protective immune responses after a single administration, and earlier this year, data presented at the World Vaccine Congress Washington demonstrated that a single dose of MVA-X achieved protective efficacy comparable to a traditional two-dose MVA regimen in a murine orthopoxvirus challenge model, with protection maintained through Day 150. This could simplify vaccination logistics and speed up deployment during outbreaks.
In parallel, GeoVax is advancing MVA production using the AGE1.CR.pIX continuous avian cell line as an alternative to traditional chicken embryo fibroblast (CEF)-based manufacturing. The company has demonstrated proof-of-concept for the upstream process, and the downstream process is in development to support production at the 200-liter scale, with a pathway toward 500-liter and larger-scale manufacturing. This approach is designed to enable scalable, reproducible production, reduce reliance on primary-cell supply chains, and facilitate technology transfer. Such flexibility could be crucial for rapidly increasing vaccine supply in response to pandemics or biodefense needs.
David A. Dodd, Chairman and CEO of GeoVax, commented, “MVA is an important and well-established vaccine platform, and we believe there are significant opportunities to further improve how MVA-based vaccines are administered and manufactured. Our work with MVA-X and AGE1.CR.pIX addresses both sides of that equation – potentially simplifying vaccination through a single-dose approach while establishing a scalable manufacturing platform capable of supporting broader and more responsive vaccine supply.” He added that the conference provides an opportunity to share progress with the global vaccine community, with implications for outbreak response, pandemic preparedness, biodefense, strategic stockpiling, and expanded global access to MVA-based vaccines.
GeoVax’s priority program is GEO-MVA, an MVA-based vaccine targeting mpox and smallpox, advancing under an expedited regulatory pathway with plans to initiate a pivotal Phase 3 trial in the second half of 2026. In oncology, the company is developing Gedeptin®, a gene-directed enzyme prodrug therapy. For more information, visit www.geovax.com.
The World Vaccine Congress Europe 2026 presentation underscores GeoVax’s commitment to innovation and could signal a significant evolution in vaccine technology, with potential benefits for global health security and patient access.
